Cyberonics reneged on its "Lifetime Reimbursement Guarantee". Click on the image to learn how you can help...
Showing posts with label antidepressant medication. Show all posts
Showing posts with label antidepressant medication. Show all posts

Wednesday, September 11, 2013

VNS Therapy – Conversation with Mr. Jonathan Blum – CMS

From: Joyce and Herbert Stein [mailto:fabrik@bellsouth.net]
Sent: Wednesday, September 11, 2013 2:41 PM
Subject: VNS Therapy "Compassionate use" for depression patients...

To all of Joyce’s fellow implant depression patients,

In trying to keep you all informed to the best of my ability and to which I am allowed to publicly share information as it relates to my efforts to obtain a favorable “Compassionate use” determination for all the patients implanted for depression on/or before May 4, 2007 I would like to share some information.  While I have not yet achieved my goal you should know the following as I continue advocating for you all.

I would first and most importantly like to thank Mr. Jonathan Blum - CMS for taking his valuable time to speak with me personally to better understand Joyce’s and your very serious medical issues requiring immediate attention.  Quite frankly, I expected to be listening to Jonathan but he threw me a curve ball and I awkwardly did most of the speaking.  By the way, please also forgive my southern drawl if y’all don’t understand my speech.  I grew up in the deep South; that is South Brooklyn (joke).

My telephone conversation with Mr. Jonathan Blum – CMS

Joyce and I shall be leaving on Tuesday, September 17th to New York to attend our eldest granddaughter’s Bat Mitzvah.  We shall return on Tuesday, September 24th so I’ll be less available by computer for the week but my phone is on 24/7 if you folks need support.

Sincerely,

Herb

Joyce and Herbert Stein

1008 Trailmore Lane

Weston, FL 33326-2816

(954) 349-8733

vnsdepression@gmail.com

http://www.vnstherapy-herb.blogspot.com

http://vnstherapy.wordpress.com/

---------------------------------------------------------------

NOTICE OF CONFIDENTIALITY / Disclaimer

---------------------------------------------------------------

Disclaimer: This E-Mail is covered by the Electronic Communications Privacy Act, 18 U.S.C. §§ 2510-2521 and is legally privileged. The information contained in this E-Mail is intended only for use of the individual or entity named above. If the reader of this message is not the intended recipient, or the employee or agent responsible for delivering it to the intended recipient, you are hereby notified that any dissemination, distribution, or copying of this communication is strictly prohibited. If you receive this E-Mail in error, please notify the sender immediately at the email address and/or phone number above and delete the information from your computer. Please do not copy or use it for any purpose nor disclose its contents to any other person.

CONFIDENTIALITY NOTICE: This e-mail message including attachments, if any, is intended only for the person or entity to which it is addressed and may contain confidential and/or privileged material. Any unauthorized review, use, disclosure or distribution is prohibited. If you are not the intended recipient, please contact the sender by reply e-mail, destroy all copies of the original message, and do not disseminate it further. If you are the intended recipient but do not wish to receive communications through this medium, please advise the sender immediately.

Tuesday, July 2, 2013

The Half-Trillion-Dollar Depression

It’s the Economy

The Half-Trillion-Dollar Depression

Illustration by Jasper Rietman

By CATHERINE RAMPELL
Published: July 2, 2013

Eliza, who asked that I not disclose her last name, successfully battled depression for most of her life. She persevered through college and graduate school and worked steadily for more than a decade as a pharmacist. Then, about two years ago, she suffered from an unusually debilitating stretch in which she didn’t respond to antidepressants, and her insurance company refused to pay for experimental treatments that her doctors recommended. Now in her 40s, she has become one of the more than 1.4 million Americans on the federal disability rolls for mood disorders. She also receives Medicaid, food stamps and fuel assistance. “I never wanted a handout,” Eliza told me last month, adding that she has held on to her pharmacy license in the hope that her condition may yet improve. “I would give anything to get out of this and go back to where I was before.”

Mental illness has been an increasingly significant health concern over the past several decades, but it’s now becoming an economic one too. The number of Americans who receive Social Security Disability Insurance for mental disorders has doubled during the past 15 years. Eliza is now one of an estimated 11.5 million American adults with a debilitating mental illness, on whom the country spends about $150 billion annually on direct medical costs — therapy, drugs, hospitalizations and so forth. But the biggest blow to the overall economy are the many hidden, indirect costs. People with serious mental illness earn, on average, $16,000 less than their mentally well counterparts, totaling about $193 billion annually in lost earnings, according to a 2008 study published in The American Journal of Psychiatry. And many mentally ill workers, who are more likely to miss work, also suffer from what social scientists call presenteeism — the opposite of absenteeism — in which they are very likely to be less productive on the job when they show up.

Reduced earnings and a lower likelihood of being, or staying, married compound the problem. The mentally ill are at higher risk of poverty than their peers, which subsequently increases their need for other public safety-net services like food stamps and subsidized housing. Their use of those services, according to one recent estimate, probably costs taxpayers another $140 billion to $160 billion a year. All together, our cumulative mental-health issues — depression, schizophrenia and bipolar disorder, among others — are costing the U.S. economy about a half-trillion dollars. That’s more than the government spent on all of Medicare during the last fiscal year.

With a major expansion of health insurance slated to take effect next year under Obamacare, policy makers are obsessing over how to bring down such costs. But listening to Eliza talk about getting back to work, it was hard not to wonder whether the best way to cut the long-term costs associated with mental illness was, paradoxically, to spend more money on directly treating it now. Economists refer to this as the cost offset, and it’s sort of like a return on an investment that comes from helping mentally ill people become more productive and less dependent on taxpayers.

There is evidence that suggests this might work. A study published in 2007 in The Journal of the American Medical Association, for example, enrolled depressed employees at 16 large companies in a randomized controlled trial. Some of them received telephone outreach, care management and optional psychotherapy, while others received their usual care. The employees in the “enhanced care” group not only worked longer weeks than those in the other group but also demonstrated greater job retention. Those increases in hours on the job brought companies an average annual value of $1,800 per worker, which was estimated to exceed the cost of both the outreach program and the roughly 10 additional mental-health specialty visits made by subjects in the treatment group. Another study conducted at 12 primary-care facilities found increased productivity and reduced absenteeism for patients who received enhanced treatment.

The question is whether those findings will apply on a much larger scale. Obamacare — coupled with another recent law that forces insurers to cover behavioral-health care the same way they cover other medical care — will significantly increase coverage for mental illness for about 62.5 million people. And there is one subtle way that this expansion of coverage could improve Americans’ outcomes almost immediately. The recent Oregon Medicaid experiment, in which poor people received Medicaid coverage by lottery, found that having health coverage didn’t necessarily improve outcomes for certain physical ailments, like diabetes, but it did reduce rates of depression by 30 percent, even though antidepressant use barely increased. The mere fact that people didn’t have to worry about a costly medical emergency, researchers deduced, may have helped reduce rates of depression.

The main way expanded coverage would help people with mental illness, though, would be to get more of them into successful treatment. And Obamacare alone won’t get that done. Even though tens of millions of people will get more coverage, estimates suggest that only 1.15 million new users will take advantage of mental-health services. A lot of people who will be extended coverage don’t need care; others, fearful of the stigma around mental health, may not take it. What’s more distressing, from both an economic and a social perspective, is that a lot of people who do muster the courage still won’t get the right kind of treatment. About half of Americans who seek care for serious mental illnesses get treatment that does not help them or is not even recommended for their condition. Some, like Eliza, have illnesses that are resistant to first-line antidepressants. It took years before she could get her insurance company to foot the bill for an alternate treatment that her doctors said was medically necessary. By then she had already fallen into poverty.

One way to address the quality-of-care issue is to invest in more comparative-effectiveness research, which is a fancy term for pitting health care options head to head to see which works best for which patients and under what circumstances. Economists have long advocated this as a way to ensure we’re spending our money more wisely, but the United States sponsors surprisingly little of it. There’s a popular distaste for anything that smacks of government telling doctors or patients what to do. Also comparative-effectiveness research is ridiculously expensive. But just as it’s important to think dispassionately about the costs and benefits of expanding mental-health-care insurance, its also important to think dispassionately about what we spend our mental-health-care dollars on. If we want to realize the long-term economic and social benefits that come from helping people burdened by mental illness, we may have to endure some short-term economic pain.

Catherine Rampell is an economics reporter for The Times. Adam Davidson is off this week.

http://www.nytimes.com/2013/07/02/magazine/the-half-trillion-dollar-depression.html?pagewanted=all&_r=0

Thursday, June 20, 2013

Brain Scans Predict Best Course of Treatment for Patients with Depression

Brain Scans Predict Best Course of Treatment for Patients with Depression


Helen S. Mayberg, M.D., of Emory University, an expert on depression
Helen S. Mayberg, M.D.
 
Brain & Behavior Research Foundation Scientific Council Member and three-time NARSAD Grantee Helen S. Mayberg, M.D., was principal investigator for a study that showed that specific patterns of brain activity can help indicate how a depressed person will respond to treatment with medication or psychotherapy. The study results, published in JAMA Psychiatry online on June 12, 2013, offer a first step towards personalized medicine treatment decisions for major depression. The findings are especially important because at present less than half of patients experience remission with the treatment initially selected.
 
Dr. Mayberg has long been committed to improving the lives of patients with depression and other mental illnesses. She pioneered the use of positron emission tomography (PET) to investigate brain changes in depressed patients with her first NARSAD Young Investigator Grant 20 years ago. Since that time, with the support of two further NARSAD Grants―and countless other grants―she successfully identified a key locus of pathology in depression (the subcallosal cingulate or Brodmann Area 25) and piloted the use of deep brain stimulation (DBS) to target this “Area 25” to treat patients with resistant depression.
 
Her new study sought to identify a biomarker that could predict which type of treatment a patient would benefit from based on the individual’s brain activity. The research team measured brain glucose metabolism (a critical brain function) in two groups of participants during a span of 12 weeks. After having a PET scan, half of the participants were given an antidepressant medication and the other half were given cognitive behavior therapy (CBT).The researchers found that less activity in the brain’s anterior insula indicated response to CBT, and more activity indicated response to medication.
 
"To be ill with depression any longer than necessary can be perilous," says Dr. Mayberg, Dorothy C. Fuqua Chair in Psychiatric Imaging and Therapeutics, Emory University School of Medicine. "This is a serious illness and the prolonged suffering resulting from an ineffective treatment can have serious medical, personal and social consequences. Our goal is not just to get patients well, but to get them well as fast as possible, using the treatment that is best for each individual."
 
"These data suggest that if you treat based on a patient's brain type, you increase the chance of getting them into remission," says Dr. Mayberg. More study is needed to confirm how this approach may be used to deliver treatments more effectively and how to apply it to different types of depression.